Resistance profile and risk factors of drug resistant tuberculosis in the Baltic countries

Tuberculosis

Volumn 95, Issue 5, 2015, Pages 581-588

  Ignatyeva, Olga ^a   Balabanova, Yanina ^b,c,d   Nikolayevskyy, Vladyslav ^b,c   Koshkarova, Ekaterina ^a   Radiulyte, Birute ^e   Davidaviciene, Edita ^e   Riekstina, Vija ^f   Jaama, Kadri ^g   Danilovits, Manfred ^g   Popa, Cristina M ^h   Drobniewski, Francis A ^b,c  

^a Samara Oblast Tuberculosis Dispensary   (Russian Federation)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ROBERT KOCH INSTITUTE   (Germany)

^e National Tuberculosis and Infectious Diseases University Hospital   (Lithuania)

^f RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^g TARTU UNIVERSITY CLINICS   (Estonia)

^h Marius Nasta Institute   (Romania)

Author keywords

Baltic countries; Clinical management; Multi extensive drug resistant tuberculosis; Risk factors

Indexed keywords

AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ALCOHOL ABUSE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG ABUSE; EDUCATIONAL STATUS; EMPLOYMENT; ESTONIA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HEPATITIS C; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATVIA; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; SMOKING; URBAN AREA; BALTIC STATES; CLINICAL TRIAL; COMORBIDITY; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; RETROSPECTIVE STUDY; SOCIOECONOMICS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; BALTIC STATES; COMORBIDITY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84940459125     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2015.05.018     Document Type: Article

References (46)

1. World Health Organization Global tuberculosis report WHO/HTM/TB/201408 2014
2. C.Y. Chiang, A. Van Deun, and D.A. Enarson A poor drug-resistant tuberculosis programme is worse than no programme: time for a change Int J Tuberc Lung Dis 17 6 2013 714 718 10.5588/ijtld.12.0989
3. R. Koenig Drug-resistant tuberculosis. In South Africa, XDR TB and HIV prove a deadly combination Science 319 5865 2008 894 897 10.1126/science.319.5865.894 319/5865/894 [pii]
4. H. Cox, Y. Kebede, S. Allamuratova, G. Ismailov, Z. Davletmuratova, G. Byrnes, and et al. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance PLoS Med 3 10 2006 e384 doi:05-PLME-RA-0653R3 [pii]
5. G.B. Migliori, G. Sotgiu, M. D'Arcy Richardson, R. Centis, A. Facchini, G. Guenther, and et al. MDR-TB and XDR-TB: drug resistance and treatment outcomes Eur Respir J 34 3 2009 778 779 10.1183/09031936.00059409
6. S.C. Resch, J.A. Salomon, M. Murray, and M.C. Weinstein Cost-effectiveness of treating multidrug-resistant tuberculosis PLoS Med 3 7 2006 e241 doi:05-PLME-RA-0321R3 [pii]
7. H. Cox, and N. Ford The scourge of tuberculosis and anti-tuberculosis drug resistance in Eastern Europe Public Health Action 4 2 2014 1 2
8. C.D. Acosta, A. Dadu, A. Ramsay, and M. Dara Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward Public Health Action 4 2 2014 3 12
9. I. Lucenko, V. Riekstina, J. Perevoscikovs, D. Mozgis, M. Khogali, J. Gadoev, and et al. Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006-2010 Public Health Action 4 2 2014 54 58
10. European Centre for Disease Prevention and Control Tuberculosis surveillance and monitoring in Europe 2015 10.2900/666960
11. F.G. Cobelens, E. Heldal, M.E. Kimerling, C.D. Mitnick, L.J. Podewils, R. Ramachandran, and et al. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda PLoS Med 5 7 2008 e150 10.1371/journal.pmed.0050150
12. S. Siddiqi, and S. Rusch-Gerdes MGIT procedure manual for BACTEC MGIT 960 TB system (also applicable for manual MGIT). Mycobacteria growth indicator tube (MGIT) culture and drug susceptibility demonstration projects FIND 2006 89
13. D. Hillemann, S. Rusch-Gerdes, and E. Richter Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens J Clin Microbiol 45 8 2007 2635 2640 doi:JCM.00521-07 [pii]
14. S. Rusch-Gerdes, G.E. Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials J Clin Microbiol 44 3 2006 688 692 doi:44/3/688 [pii]
15. A. Kruuner, M.D. Yates, and F.A. Drobniewski Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis J Clin Microbiol 44 3 2006 811 818 doi:44/3/811 [pii]
16. S. Rusch-Gerdes, C. Domehl, G. Nardi, M.R. Gismondo, H.M. Welscher, and G.E. Pfyffer Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs J Clin Microbiol 37 1 1999 45 48
17. P. Bemer, F. Palicova, S. Rusch-Gerdes, H.B. Drugeon, and G.E. Pfyffer Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis J Clin Microbiol 40 1 2002 150 154
18. G.E. Pfyffer, F. Palicova, and S. Rusch-Gerdes Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system J Clin Microbiol 40 5 2002 1670 1674
19. D. Hillemann, S. Hoffner, D. Cirillo, F. Drobniewski, E. Richter, and S. Rusch-Gerdes First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries PLoS One 8 10 2013 e76765 10.1371/journal.pone.0076765
20. T. Dalton, P. Cegielski, S. Akksilp, L. Asencios, J. Campos Caoili, S.N. Cho, and et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study Lancet 380 9851 2012 1406 1417 10.1016/S0140-6736(12)60734-X
21. K. Toit, A. Altraja, D. Acosta, P. Viiklepp, K. Kremer, T. Kummik, and et al. A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission Public Health Action 4 2 2014 37 43
22. A. Skrahina, H. Hurevich, A. Zalutskaya, E. Sahalchyk, A. Astrauko, S. Hoffner, and et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors Bull World Health Organ 91 1 2013 36 45 10.2471/BLT.12.104588
23. A. Faustini, A.J. Hall, and C.A. Perucci Risk factors for multidrug resistant tuberculosis in Europe: a systematic review Thorax 61 2 2006 158 163 doi:thx.2005.045963 [pii]
24. C.M. Clark, J. Li, C.R. Driver, and S.S. Munsiff Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City Int J Tuberc Lung Dis 9 9 2005 964 969
25. M.A. Espinal, K. Laserson, M. Camacho, Z. Fusheng, S.J. Kim, R.E. Tlali, and et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries Int J Tuberc Lung Dis 5 10 2001 887 893
26. M. Ruddy, Y. Balabanova, C. Graham, I. Fedorin, N. Malomanova, E. Elisarova, and et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia Thorax 60 2 2005 130 135 doi:60/2/130 [pii]
27. S. Hirpa, G. Medhin, B. Girma, M. Melese, A. Mekonen, P. Suarez, and et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study BMC Public Health 13 2013 782 10.1186/1471-2458-13-782
28. Y. Balabanova, B. Radiulyte, E. Davidaviciene, R. Hooper, O. Ignatyeva, V. Nikolayevskyy, and et al. Risk factors for drug-resistant tuberculosis patients in Lithuania, 2002-2008 Eur Respir J 39 5 2012 1266 1269 10.1183/09031936.00133911
29. L. Kuksa, V. Riekstina, V. Leimane, I. Ozere, G. Skenders, R. Van den Bergh, and et al. Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes Public Health Action 4 2 2014 47 53
30. P. Zhao, X.J. Li, S.F. Zhang, X.S. Wang, and C.Y. Liu Social behaviour risk factors for drug resistant tuberculosis in mainland China: a meta-analysis J Int Med Res 40 2 2012 436 445
31. A. Farazi, M. Sofian, N. Zarrinfar, F. Katebi, S.D. Hoseini, and R. Keshavarz Drug resistance pattern and associated risk factors of tuberculosis patients in the central province of Iran Casp J Intern Med 4 4 2013 785 789
32. A.C. Miller, I.Y. Gelmanova, S. Keshavjee, S. Atwood, G. Yanova, S. Mishustin, and et al. Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation Int J Tuberc Lung Dis 16 7 2012 891 896 10.5588/ijtld.11.0795
33. E.A. Kendall, D. Theron, M.F. Franke, P. van Helden, T.C. Victor, M.B. Murray, and et al. Alcohol, hospital discharge, and socioeconomic risk factors for default from multidrug resistant tuberculosis treatment in rural South Africa: a retrospective cohort study PLoS One 8 12 2013 e83480 10.1371/journal.pone.0083480
34. H. Connery, S. Greenfield, V. Livchits, L. McGrady, N. Patrick, C.S. Lastimoso, and et al. Training and fidelity monitoring of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia: the IMPACT effectiveness trial Subst Use Misuse 48 9 2013 784 792 10.3109/10826084.2013.793715
35. S. Shin, V. Livchits, H.S. Connery, A. Shields, S. Yanov, G. Yanova, and et al. Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia Addiction 108 8 2013 1387 1396 10.1111/add.12148
36. P. Viiklepp, P. de Colombani, A. Kurbatova, A. Sandgren, and K. Lonnroth Collaborative action on tuberculosis and alcohol abuse in Estonia: first report of a demonstration project 2013
37. V. Leimane, G. Dravniece, V. Riekstina, I. Sture, S. Kammerer, M.P. Chen, and et al. Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004 Eur Respir J 36 3 2010 584 593 10.1183/09031936.00003710
38. E.V. Kurbatova, A. Taylor, V.M. Gammino, J. Bayona, M. Becerra, M. Danilovitz, and et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects Tuberculosis (Edinb) 92 5 2012 397 403 10.1016/j.tube.2012.06.003
39. V. Skripconoka, M. Danilovits, L. Pehme, T. Tomson, G. Skenders, T. Kummik, and et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis Eur Respir J 41 6 2013 1393 1400 10.1183/09031936.00125812
40. V.M. Gammino, A.B. Taylor, M.L. Rich, J. Bayona, M.C. Becerra, C. Bonilla, and et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects Int J Tuberc Lung Dis 15 10 2011 1315 1322 10.5588/ijtld.10.0221
41. L. Vashakidze, A. Salakaia, N. Shubladze, M. Cynamon, K. Barbakadze, M. Kikvidze, and et al. Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia Int J Tuberc Lung Dis 13 9 2009 1148 1153
42. I. Mokrousov, T. Otten, T. Zozio, E. Turkin, V. Nazemtseva, A. Sheremet, and et al. At Baltic crossroads: a molecular snapshot of Mycobacterium tuberculosis population diversity in Kaliningrad, Russia FEMS Immunol Med Microbiol 55 1 2009 13 22 10.1111/j.1574-695X.2008.00470.x
43. E. Chernyaeva, P. Dobrynin, N. Pestova, N. Matveeva, V. Zhemkov, and A. Kozlov Molecular genetic analysis of Mycobacterium tuberculosis strains spread in different patient groups in St. Petersburg, Russia Eur J Clin Microbiol Infect Dis 31 8 2012 1753 1757 10.1007/s10096-011-1497-2
44. Y. Balabanova, V. Nikolayevskyy, O. Ignatyeva, I. Kontsevaya, C.M. Rutterford, A. Shakhmistova, and et al. Survival of civilian and prisoner drug-sensitive, multi- and extensive drug-resistant tuberculosis cohorts prospectively followed in Russia PLoS One 6 6 2011 e20531 10.1371/journal.pone.0020531
45. N. Casali, V. Nikolayevskyy, Y. Balabanova, S.R. Harris, O. Ignatyeva, I. Kontsevaya, and et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population Nat Genet 46 3 2014 279 286 10.1038/ng.2878
46. A. Kruuner, S.E. Hoffner, H. Sillastu, M. Danilovits, K. Levina, S.B. Svenson, and et al. Spread of drug-resistant pulmonary tuberculosis in Estonia J Clin Microbiol 39 9 2001 3339 3345